1-4 of 4
Suliman Al-Fayoumi
Close
Sort by
Journal Articles

Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts <100,000/µl

John Mascarenhas, Ronald Hoffman, Moshe Talpaz, Aaron T. Gerds, Brady Stein, Vikas Gupta, Anita Szoke, Mark Drummond, Alexander Pristupa, Tanya Granston, Robert Daly, James P. Dean, Suliman Al-Fayoumi, Jennifer A. Callahan, Jack W. Singer, Jason Gotlib, Catriona Jamieson, Claire Harrison, Ruben Mesa, Srdan Verstovsek
Journal: Blood
Blood (2016) 128 (22): LBA-5.
https://doi.org/10.1182/blood.V128.22.LBA-5.LBA-5
Published: 2016
Journal Articles

Clinical Pharmacology Profile of Pacritinib (PAC), a Novel JAK2/FLT3 Inhibitor

Suliman Al-Fayoumi, Mary S. Campbell, Sherri Amberg, Huafeng Zhou, Lindsey Millard, James P. Dean
Journal: Blood
Blood (2015) 126 (23): 5178.
https://doi.org/10.1182/blood.V126.23.5178.5178
Published: 2015
Journal Articles

Comprehensive Kinase Profile of Pacritinib, a Non-Myelosuppressive JAK2 Kinase Inhibitor in Phase 3 Development in Primary and Post ET/PV Myelofibrosis

Jack Singer, MD, Suliman Al-Fayoumi, PhD MBA, Haiching Ma, Rami S Komrokji, MD, Ruben Mesa, MD, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2014) 124 (21): 1874.
https://doi.org/10.1182/blood.V124.21.1874.1874
Published: 2014
Journal Articles

Exposure-Response Analysis For Pacritinib (SB1518), a Novel Oral JAK2/FLT3 Inhibitor, In Patients With Myelofibrosis

Suliman Al-Fayoumi, PhD, MBA, Lixia Wang, PhD, Hanbin Li, PhD, Russ Wada, PhD, James P. Dean, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 4080.
https://doi.org/10.1182/blood.V122.21.4080.4080
Published: 2013